ReviewJournal of Korean biological nursing science2026
Reporting quality of systematic reviews published from 2011 to 2024 in the
Review in Journal of Korean biological nursing science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study evaluated the reporting quality of systematic reviews (SRs) published in the Methods: A methodological review was conducted using articles retrieved from the JKBNS archive. The literature search was performed between October 7 and October 24, 2025. Two reviewers independently screened all records, and reporting quality was assessed using the 27 PRISMA items and 42 associated sub-items, which were scored as fully reported (1), partially reported (0.5), or not reported (0). Compliance rates were calculated, and PRISMA items were mapped to corresponding AMSTAR-2 and ROBIS domains. Results: Twenty SRs and meta-analyses met the inclusion criteria. The mean score across PRISMA sub-items was 23.58 ± 7.34 (range, 15~38). Ten sub-items-including rationale, objectives, information sources, search strategy, data collection, study selection and exclusion, study characteristics, and key discussion elements-were consistently reported. In contrast, protocol registration, protocol access, and sensitivity analyses were rarely reported, while certainty assessment, certainty of evidence, and protocol amendments were not reported in any study. Overall adherence to the 27 PRISMA items was 64.7 ± 14.9% (range, 44.4~92.6). Conclusion: Conceptual mapping demonstrated strong alignment between PRISMA methodology and results items and the domains of AMSTAR-2 and ROBIS; however, transparency-focused components newly introduced in PRISMA 2020 showed limited correspondence. These findings provide practical guidance for improving reporting transparency in future SRs published in JKBNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.